| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 09/01/2024 | 12:12 | IH Market News | Wall Street Highlights: HPE and Juniper Networks in Negotiations, Elliott Invests $1 Billion in Match Group, and More | NASDAQ:SGEN | Seagen Inc |
| 26/12/2023 | 12:12 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:SGEN | Seagen Inc |
| 19/12/2023 | 00:46 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SGEN | Seagen Inc |
| 18/12/2023 | 23:25 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:SGEN | Seagen Inc |
| 15/12/2023 | 23:00 | PR Newswire (US) | PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer | NASDAQ:SGEN | Seagen Inc |
| 14/12/2023 | 14:47 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:SGEN | Seagen Inc |
| 14/12/2023 | 14:29 | Edgar (US Regulatory) | Form POSASR - Post-effective Amendment to an automatic shelf registration statement | NASDAQ:SGEN | Seagen Inc |
| 14/12/2023 | 14:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SGEN | Seagen Inc |
| 14/12/2023 | 14:00 | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities | NASDAQ:SGEN | Seagen Inc |
| 12/12/2023 | 13:43 | Dow Jones News | Pfizer to Close $43 Billion Seagen Acquisition This Week | NASDAQ:SGEN | Seagen Inc |
| 11/12/2023 | 01:30 | Business Wire | ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma | NASDAQ:SGEN | Seagen Inc |
| 06/12/2023 | 14:15 | Business Wire | TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer | NASDAQ:SGEN | Seagen Inc |
| 01/12/2023 | 00:04 | Dow Jones News | Astellas, Seagen: Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority Review | NASDAQ:SGEN | Seagen Inc |
| 30/11/2023 | 23:00 | Business Wire | FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer | NASDAQ:SGEN | Seagen Inc |
| 14/11/2023 | 03:37 | Edgar (US Regulatory) | Form 144/A - Report of proposed sale of securities: [Amend] | NASDAQ:SGEN | Seagen Inc |
| 14/11/2023 | 00:37 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:SGEN | Seagen Inc |
| 03/11/2023 | 17:00 | Business Wire | Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting | NASDAQ:SGEN | Seagen Inc |
| 02/11/2023 | 18:00 | Business Wire | New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate | NASDAQ:SGEN | Seagen Inc |
| 01/11/2023 | 13:31 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SGEN | Seagen Inc |
| 01/11/2023 | 13:00 | Business Wire | Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress | NASDAQ:SGEN | Seagen Inc |
| 22/10/2023 | 16:30 | Business Wire | TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial | NASDAQ:SGEN | Seagen Inc |
| 22/10/2023 | 16:30 | Business Wire | Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer | NASDAQ:SGEN | Seagen Inc |
| 20/10/2023 | 13:22 | IH Market News | Friday’s Wall Street Highlights: SolarEdge, Intuitive Surgical, Knight-Swift, HPE, and more | NASDAQ:SGEN | Seagen Inc |
| 16/10/2023 | 14:00 | Business Wire | Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023 | NASDAQ:SGEN | Seagen Inc |
| 12/10/2023 | 14:00 | Business Wire | Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023 | NASDAQ:SGEN | Seagen Inc |
| 22/09/2023 | 13:02 | Dow Jones News | Merck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits Endpoints | NASDAQ:SGEN | Seagen Inc |
| 22/09/2023 | 11:00 | Business Wire | PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial | NASDAQ:SGEN | Seagen Inc |
| 18/09/2023 | 13:25 | IH Market News | Monday’s Wall Street Highlights: Cisco Systems, GM, Alibaba, SVB Financial, Clorox and More | NASDAQ:SGEN | Seagen Inc |
| 04/09/2023 | 21:00 | Business Wire | Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone | NASDAQ:SGEN | Seagen Inc |
| 04/09/2023 | 21:00 | Business Wire | Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy | NASDAQ:SGEN | Seagen Inc |